France to introduce first ever blood test for bipolar disorder
France to introduce first ever blood test for bipolar disorder"
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
France is set to introduce a blood test for bipolar disorder for the first time ever, in a bid to help doctors considerably speed up diagnosis and distinguish between the condition and other
mental health issues. The test - called myEDIT-B - will be available from April 1, 2024. It comes from French start-up ALCEDIAG, led by co-founder and scientific director Dr Dinah
Weissmann. Along with the medical biology lab Synlab, whose network will be offering the tests, it said IN A PRESS RELEASE on March 22 that the blood test would be “the first ever to help
with mental health diagnoses”. It said it was aiming to offer a “more precise and early” diagnosis, giving patients a greater chance of getting on to the right medication earlier, for a much
better quality of life and more positive outcomes. It will be able to return a diagnosis within weeks, in contrast to the current average of up to 10 years. "Until now, diagnosis has
essentially been based on clinical interviews, but the emergence of precision psychiatry marks a turning point,” said Professor Chantal Henry, a psychiatrist at the GHU Paris, and Scientific
Director of the Fondation Pierre Deniker. “It is based on the discovery of objective biomarkers that complement clinical diagnosis [and] makes it possible to differentiate between
depression, bipolar disorder, and unipolar depression. This should make it possible to offer appropriate treatment for patients with bipolar disorder.” HOW DOES THE TEST WORK? The blood test
uses DNA sequencing from the patient’s blood, and also works with an AI-based ‘machine learning’ algorithm to help improve its accuracy. So far, clinical studies - including one involving
255 patients in France, published in the scientific journal Nature; and another study on 143 patents in Switzerland - found a sensitivity and specificity rate (meaning the reliability of
results) of more than 80%. The test also takes into account patients’ age, sex, medical treatments, and any addictions they may have. WHO CAN GET A TEST? Only a psychiatrist will be able to
order the test, and patients will need to visit one of the Synlab laboratories - there are around 380 of them nationwide - to undertake it. They will need to present a psychiatrist
prescription ordering the test, as well as a clinical information form signed by the doctor, and sign a consent form for the conditions of use of the test. The results take four weeks to
come back to the prescribing psychiatrist, who can then use them to help confirm their diagnosis with a patient during a consultation, the group said. It will only be available for adults
who are already "being treated for a moderate or severe episode of depression", and whose treating psychiatrist believes they could have bipolar disorder. Figures from the Haute
Autorité de Santé (HAS) show that between 1% and 2.5% of the French population (up to 1,600,000 people) have bipolar disorder. IMAGE: SYNLAB.FR WHAT IS BIPOLAR DISORDER? The mental health
condition used to be known as ‘manic depression’ because it typically presents as mental states that alternate between episodes of ‘high’ mania, and ‘low’ severe depression. Manic states are
characterised by a newly-intense interest in work or social activities, impulse spending or sexual activity, a sense of grandeur or a feeling of power, major difficulty in paying attention,
a need to communicate or share ideas constantly, and a major reduction in sleep. In contrast, depressive episodes are characterised by a loss of interest in normal activities, a feeling of
sadness and despair, suicide ideation, a lack of humour or attention, a slowing of thoughts and actions, and overwhelming tiredness or lethargy. There are two types of bipolar disorder: Type
I, characterised by at least one ‘manic or mixed’ episode, and Type II, characterised by one or several episodes of major depression and at least one episode of mania. The condition can be
particularly difficult to diagnose and treat (especially as it can be confused with other mental health issues), with Synlab estimating that the average diagnosis takes eight to 10 years,
from the patient’s first visit to the doctor to definite diagnosis. It can often be based on ‘trial and error’. BIPOLAR DANGERS AND ‘CAUSE’ Bipolar issues often first start to appear in
patients from age 18-24, and the condition is classified as one of the World Health Organization’s top 10 most-disabling pathologies. Up to 50% of patients may attempt to commit suicide
during their lifetime, and 15% will succeed in their attempt. Synlab states that studies show that of the 300 million people in the world diagnosed with depression, up to 40% could be
wrongly diagnosed and may actually have bipolar disorder. The condition has no single clear cause, and is suspected to be a mix of genetic, biological, psychological and socio-environmental
factors. There is a strong family predisposition, with the risk of developing the condition 10 times more likely if a parent or other first-degree relative also has it. Bipolar disorder
cannot be ‘cured’, but with medication and therapy it can be well-managed and give patients a good and stable quality of life. “Our aim with myEDIT-B is to to help psychiatrists reduce the
time taken to diagnose bipolar disorder, from several years to a few weeks (initially) and then, we hope, to a few days,” said Alexandra Prieux, president of ALCEDIAG. “We see it as an
important step towards achieving our mission: to help improve the health and quality of life for patients and their families through precision psychiatry, by developing innovative diagnostic
tests based on neuroscience, advanced biology and artificial intelligence techniques.” READ ALSO ‘LIFE-CHANGING’ BLOOD TEST IDENTIFIES BIPOLAR DISORDER HOW TO GET FREE MENTAL HEALTH SUPPORT
IN FRANCE
Trending News
Behavioural measures of the spectral sensitivity of the dark-adapted goldfishABSTRACT THE eye of the goldfish has a single rod photopigment with a peak spectral absorption at about 522 nm, together...
Iskra lawrence strips down to her knickers in sexy dance clipThe 26-year-old blonde beauty flaunted her toned midriff and famous curves in a pair of burgundy knickers and a long sle...
Andy murray makes confession after devastating wimbledon defeatTHE TWO-TIME KING OF SW19, 36, SUCCUMBED TO A SECOND ROUND FIVE-SET LOSS AGAINST STEFANOS TSITSIPAS AS THE WORLD NO.5 OV...
Trump condemns killing of two israeli embassy staff in d. C.Two Israeli embassy staff were killed in a shooting outside the Capital Jewish Museum in Washington, D.C. on Wednesday n...
Coinbase cfo says full contagion impact of ftx collapse still to show – wsjCoinbase CFO says full contagion impact of FTX collapse still to show – WSJ | WTVB | 1590 AM · 95.5 FM | The Voice of Br...
Latests News
France to introduce first ever blood test for bipolar disorderFrance is set to introduce a blood test for bipolar disorder for the first time ever, in a bid to help doctors considera...
Jack W Thomas | Premiere.frBiographie News Photos Vidéos Films Séries Nom de naissance Thomas Avis PoorNot so pooraveragegoodvery good Filmographie...
Phellinus linteus suppresses growth, angiogenesis and invasive behaviour of breast cancer cells through the inhibition of akt signallingABSTRACT The antitumour activity of a medicinal mushroom _Phellinus linteus_ (PL), through the stimulation of immune sys...
Coronation street and doctor who star diesA REPRESENTATIVE CONFIRMED MICHAEL MCSTAY HAS DIED AGED 92 07:34, 21 May 2025Updated 07:38, 21 May 2025 Coronation Stree...
Queen elizabeth ii has 'shown her true feelings' towards prince harryDuring the Royally Obsessed podcast, Rachel Bowie analysed Queen Elizabeth II's Instagram post. The royal expert st...